A Phase IIb Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Ulcerative Colitis (UC)
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2016
At a glance
- Drugs Eldelumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 22 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Oct 2014 Planned End Date changed from 1 Jan 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 16 May 2014 Planned End Date changed from 1 Mar 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History